WA-SCHULTZ-FAMILY-FND
Trilogy Films, the renowned production company led by award-winning Director Dawn Porter, is thrilled to announce an unprecedented collaboration with the Schultz Family Foundation to produce a feature-length documentary about one of the most iconic, politically-charged partnerships in history: the remarkable, largely untold story of Nelson and Winnie Mandela.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212248716/en/
Nelson and Winnie Mandela after his liberation from prison in South Africa on February 11, 1990. Photo by Pool BOUVET/DE KEERLE/Gamma-Rapho via Getty Images.
Based on the book by noted South African writer and scholar Jonny Steinberg, Winnie and Nelson: Portrait of a Marriage, the film will explore the Mandelas’ profound bond and how their marriage was inextricably entangled with the struggle against apartheid. The film promises an intimate portrayal of Nelson and Winnie’s marriage, delving into their vehement and volatile connection from their early years to their mutual goal of dismantling apartheid. Their journey culminates in Nelson Mandela’s historic election as South Africa’s first democratically elected President. This cinematic exploration captures the essence of their indomitable spirits and the global impact of their love and advocacy.
Dawn Porter, celebrated for her exceptional storytelling that explores the overlooked, reveals the consequences of policy and social action, champions the marginalized, and offers a fresh perspective on the familiar, is at the helm of the production. With her profound ability to craft narratives that deeply resonate with and inform audiences, Porter is poised to bring a unique lens to the enduring love story of Nelson and Winnie Mandela.
“Creating a film about Nelson Mandela’s life is an extraordinary privilege, and I am genuinely thrilled about the collaboration with the Schultz Family Foundation and Trilogy Films,” said Dawn Porter. “Nelson Mandela’s journey exemplifies the resilience and capacity for change within the human spirit. We aspire to share this incredible odyssey with audiences around the globe. But his story is incomplete without exploring the relationship with his most influential and intimate advisor – his wife Winnie. There can be no definitive Mandela story without understanding the complicated dynamics of their relationship.”
The collaboration with Trilogy Films marks the Schultz Family Foundation’s first venture into transformative storytelling projects – across scripted and documentary films and series, podcasts, and books – linked to its mission of creating greater opportunity, accessible to all. The Schultz Family Foundation’s involvement transcends financial support; it embodies a philanthropic vision and commitment to tell truthful, aspirational stories that have the power to reveal hidden narratives, spark hope, spotlight solutions, and restore confidence during a time of enormous pessimism, dissension, misinformation, and a fracturing of trust in traditional institutions, leadership, and each other.
“At its heart, Winnie and Nelson is a complicated story of leadership, conflict, love, and extraordinary sacrifice in the face of unfathomable brutality where the future of a democracy was at stake,” said Howard Schultz, co-founder of the Schultz Family Foundation and chairman emeritus of Starbucks Corporation. “My wife Sheri and I feel privileged and humbled by the opportunity to partner with such a respected and talented director as Dawn to bring this film to life. We believe in the power of human-centered, aspirational storytelling to nurture our common bonds, foster our shared humanity, and inspire the next generation of leaders, and we look forward to pursuing other projects across many different formats aligned with our family’s philanthropic work and mission.”
About Trilogy Films:
Trilogy Films, founded by award-winning director Dawn Porter, directs and produces non-fiction content that tells untold stories, shares new perspectives, and reveals the complex humanity of some of history’s most iconic figures. Porter's acclaimed films include "Gideon’s Army" (2013), "Spies of Mississippi” (2014), and “Bobby Kennedy for President” (2018). Her latest work, “Luther: Never Too Much,” debuted to rave reviews at the 2024 Sundance Film Festival and was lauded as the best of fest in multiple news outlets. 2023 was a banner year for Porter and Trilogy. The Critics Choice nominated “Lady Bird Diaries," an all archival documentary showcasing Lady Bird Johnson, premiered at the 2023 SXSW Film Festival, while her four-part docuseries "Deadlocked: How America Shaped the Supreme Court” also garnered nominations for a Critics Choice Documentary Award as well as a Film Independent Spirit Award.
About the Schultz Family Foundation:
The Schultz Family Foundation’s mission is to create greater opportunity, accessible to all. Our work is deeply rooted in the lives and values of our co-founders, Sheri and Howard Schultz, who believe talent is everywhere, but opportunity is not. We seek to apply the lessons they have learned over the decades to seed innovations and scale solutions to help young people successfully navigate the transition to adulthood and positively impact the trajectory of their lives. We are investors in unleashing potential and unlocking opportunity, working in partnership with employers, entrepreneurs, non-profits, and governments that share our aspiration of enabling everyone to access the full promise of America. For more information about the Foundation and its work: www.schultzfamilyfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212248716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom